Novartis delivery of child-friendly antimalarial hits the 100 million mark - 27 February 2012.
One hundred million treatments of Coartem
Dispersible (artemether-lumefantrine), an antimalarial developed especially for
children with 
Plasmodium falciparum malaria, have been delivered by Novartis to
39 malaria-endemic countries, Medicines for Malaria Venture (MMV) announced.
Coartem® Dispersible is the product of the partnership between MMV and
Novartis.
This is the first who prequalified
child-friendly artemisinin-combination therapy (ACT) and addresses an unmet
need for pediatric medicines. Young children in Africa are disproportionately
affected by malaria, with 86% of malaria deaths occurring in children under the
age of 5 years.
Source: www.csreurope.org
February 27 2012.